Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib

• DOI: 10.1158/1078-0432.ccr-07-0627
• Publication Date: 2007-09-17T18:33:36Z
• Authors: Toshimi Takano; Yuichiro Ohe; Koji Tsuta; Tomoya Fukui; Hiromi Sakamoto; Teruhiko Yoshida; Ukihide Tateishi; Hiroshi Nokihara; Noboru Yamamoto; Ikuo Sekine; Hideo Kunitoh; Yoshihiro Matsuno; Koh Furuta; Tomohide Tamura
• Keywords: Adult; Aged, 80 and over; Male; Lung Neoplasms; DNA Mutational Analysis; Antineoplastic Agents; Gefitinib; Middle Aged; Arginine; Prognosis; Disease-Free Survival; 3. Good health; ErbB Receptors; 03 medical and health sciences; 0302 clinical medicine; Amino Acid Substitution; Leucine; Carcinoma, Non-Small-Cell Lung; Mutation; Quinazolines; Humans; Female; Aged

Abstract Purpose: Epidermal growth factor receptor (EGFR) mutations, especially deletional mutations in exon 19 (DEL) and L858R, predict gefitinib sensitivity in patients with non–small cell lung cancer (NSCLC). In this study, we validated EGFR mutation detection using high-resolution melting analysis (HRMA) and evaluated the associations between EGFR mutations and clinical outcomes in advanced NSCLC patients treated with gefitinib on a larger scale. Experimental Design: The presence of DEL or L858R was evaluated using HRMA and paraffin-embedded tissues and/or cytologic slides from 212 patients. In 66 patients, the results were compared with direct sequencing data. Results: HRMA using formalin-fixed tissues had a 92% sensitivity and a 100% specificity. The analysis was successfully completed in 207 patients, and DEL or L858R mutations were detected in 85 (41%) patients. The response rate (78% versus 8%), time-to-progression (median, 9.2 versus 1.6 months), and overall survival (median, 21.7 versus 8.7 months) were significantly better in patients with EGFR mutations (P < 0.001). Even among the 34 patients with stable diseases, the time-to-progression was significantly longer in patients with EGFR mutations. Patients with DEL (n = 49) tended to have better outcomes than those with L858R (n = 36); the response rates were 86% and 67%, respectively (P = 0.037), and the median time-to-progression was 10.5 and 7.4 months, respectively (P = 0.11). Conclusions: HRMA is a precise method for detecting DEL and L858R mutations and is useful for predicting clinical outcomes in patients with advanced NSCLC treated with gefitinib.